News
Niagen Bioscience CEO Robert Fried discusses the science of NAD, the problems with the supplement industry, and how his company is leading the way in anti-aging research.
Executives from Niagen Bioscience, Pushly, and VidaCorp discuss brand evolution. Learn why authenticity, community, and AI are key to building a resilient brand.
9d
GlobalData on MSNNiagen Bioscience signs exclusive licence deal for PD therapyNiagen Bioscience can either commercialise the drug candidate independently or sublicense to a strategic pharmaceutical ...
3d
GlobalData on MSNEquinox Hotel launches Tru Niagen health supplement as in-room amenityThis initiative is part of the brand’s commitment to providing guests with science-backed health and wellness services.
Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine ...
View the latest Niagen Bioscience Inc. (NAGE) stock price, news, historical charts, analyst ratings and financial information from WSJ.
10d
InvestorsHub on MSNNiagen Bioscience Shares Climb Following Exclusive License for Parkinson’s TherapyNiagen Bioscience Inc. (NASDAQ:NAGE) saw its stock rise 2% after securing an exclusive global commercial license from Norway’s Haukeland University Hospital to develop its nicotinamide riboside ...
Niagen Bioscience Media Contact: Kendall Knysch, Senior Director of Media Relations & Partnerships 310-405-5227 [email protected]. Niagen Bioscience Investor Relations Contact: ...
Niagen Bioscience’s robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com, where copies of press releases, ...
Niagen Bioscience (NASDAQ:NAGE) is preparing to release its quarterly earnings on Wednesday, 2025-05-07. Here's a brief overview of what investors should keep in mind before the announcement.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results